Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

CME

Glaucoma: Part II - Treatment

In the early stages, if detected by the physician, maintenance therapy can be expected to prevent further damage over a lifetime.
CME credit is no longer available for this conference.

Course Authors

Gary M. Levin, M.D.

Dr. Levin is Clinical Assistant Professor, Department of Ophthalmology, Loma Linda University.

Within the past three years, Dr. Levin reports no commercial conflict of interest.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Discuss pharmacologic treatments for glaucoma

  • Describe the mechanism of action of the latest eye medications

  • Discuss non invasive and laser treatments for glaucoma

  • Describe surgical interventions for glaucoma.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Open Angle Glaucoma

Emerging new treatments for open angle glaucoma.
Authors: Enoch B. Kassa, M.D., and Yang Sun, M.D., Ph.D.
Estimated Time: 1 Hour
More

Age-Related Cataract

Cataract is the leading cause of blindness in the world. While surgical treatment is curative, it is not widely available in developing countries.
Authors: Enoch B. Kassa, M.D., and Yang Sun, M.D., Ph.D.
Estimated Time: 1 Hour
More

Never Turn A Blind Eye: Amblyopia - causes, treatment and outcomes

Amblyopia, or “lazy eye,” is the most common cause of monocular visual impairment in both children and young adults.
Authors: Courtney L. Kraus, M.D., and Susan M. Culican, M.D., Ph.D.
Estimated Time: 1 Hour
More

Physiology of Contact Lens Systems

This month, Barry A. Weissman, O.D., Ph.D. discusses

in view of ever evolving practice patterns with evidence-based medicine, the reader is urged to always evaluate each case and treatment individually at the time of evaluation, and to always consult the most up-to-date sources including drug package inserts, etc., prior to embarking upon treatment. Glossary of Abbreviations (in order of
Authors: Barry A. Weissman, O.D., Ph.D.
Estimated Time: 1 Hour
More

Age-related Macular Degeneration (AMD)

The cause of AMD is unclear but it likely results from a combination of oxidative damage, microvascular disease and genetic predisposition.
Authors: Leon Charkoudian, M.D., and Joshua L. Dunaief, M.D., Ph.D.
Estimated Time: 1 Hour
More

Ocular Lens Structure and Mechanisms of Cataract Formation: Part II

This month, Val Shestopalov, Ph.D., discusses

active cells and possesses active mechanisms for homeostasis, preserving proteins from photooxidation and aggregation throughout an individual's life. This is achieved through four major mechanisms: actively lowering oxygen content in the lens center synthesis of potent anti-oxidants scavenging reactive oxygen species synthesis of large amounts of molecular chaperones preserving protein
Authors: Val Shestopalov, Ph.D.
Estimated Time: 1 Hour
More